Pascale Lejeune

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.

Journal: Journal for immunotherapy of cancer
Published: September 06, 2021

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2021

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2019

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.

Journal: Molecular cancer therapeutics
Published: January 14, 2019

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.

Journal: Leukemia
Published: October 25, 2018

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.

Journal: International journal of cancer
Published: October 05, 2018

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.

Journal: Nature medicine
Published: September 06, 2017

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Journal: European urology
Published: May 25, 2017

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Journal: British journal of haematology
Published: February 10, 2017

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.

Journal: Oncogene
Published: October 26, 2016

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.

Journal: Cell death & disease
Published: May 19, 2016

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.

Journal: Oncotarget
Published: October 22, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026